Photo of Dr. Edith A. Nutescu PharmD, MS CTS, FCCP

Edith A. Nutescu, PharmD, MS CTS, FCCP


Professor and Head, Pharmacy Practice
Center Affiliate, Center for Pharmacoepidemiology and Pharmacoeconomic Research
Department Affiliate, Pharmacy Systems, Outcomes and Policy

Contact

Building & Room:

Room 164, College of Pharmacy

Address:

833 South Wood Street, Chicago, IL, 60612

Office Phone:

(312) 996-0880

Email:

enutescu@uic.edu

About

Research Interests: Dr. Nutescu's areas of interest and research include Health Services and Outcomes Research, Cardiovascular Thrombosis, Safety and Comparative Effectiveness of Antithrombotic Agents, Patient Centered Self-Care and Behavioral Interventions, Patient Reported Outcomes (Quality of Life), Effectiveness of Clinical Pharmacy Services and Interventions

Selected Publications

  • Gor D, Gerber BS, Walton SM, Lee TA, Nutescu EA, Touchette D. Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey.. Journal of diabetes. 2019;. doi:10.1111/1753-0407.13003.

  • Lee I, Adimadhyam S, Nutescu EA, Zhou J, Asfaw AA, Sweiss KI, Patel PR, Calip GS. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.. Pharmacotherapy. 2019;39(9):921-928. doi:10.1002/phar.2310.

  • Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS. (2019). Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al.. British journal of haematology. Vol. 186. Issue 5. Page(s) 782-783.

  • Ohara M, Suzuki Y, Shinohara S, Gong IY, Schmerk CL, Tirona RG, Schwarz UI, Wen MS, Lee MTM , Mihara K, Nutescu EA, Perera MA, Cavallari LH, Kim RB, Takahashi H. Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.. Clinical pharmacokinetics. 2019;58(8):1077-1089. doi:10.1007/s40262-019-00745-5.

  • Friedman PN, Shaazuddin M, Gong L, Grossman RL, Harralson AF, Klein TE, Lee NH, Miller DC, Nutescu EA, O’Brien TJ, O’Donnell PH, O’Leary KJ, Tuck M, Meltzer DO, Perera MA. The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans.. Clinical and translational science. 2019;12(3):209-217. doi:10.1111/cts.12608.

  • Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS. Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.. British journal of haematology. 2019;185(1):116-127. doi:10.1111/bjh.15773.

  • Zhou J, Han J, Nutescu EA, Patel PR, Sweiss KI, Calip GS. Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study.. Pharmacotherapy. 2019;39(1):55-66. doi:10.1002/phar.2197.

  • Zhou J, Han J, Nutescu EA, Gordeuk VR, Saraf SL, Calip GS. Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.. British journal of haematology. 2018;182(2):259-270. doi:10.1111/bjh.15396.

  • Sharabiani A, Nutescu EA, Galanter WL, Darabi H. A New Approach towards Minimizing the Risk of Misdosing Warfarin Initiation Doses.. Computational and mathematical methods in medicine. 2018;2018:5340845. doi:10.1155/2018/5340845.

  • Lee YM, Manzoor BS, Cavallari LH, Nutescu EA. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.. Pharmacotherapy. 2018;38(2):205-216. doi:10.1002/phar.2077.

  • Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB , Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.. JACC. Cardiovascular interventions. 2018;11(2):181-191. doi:10.1016/j.jcin.2017.07.022.

  • Kubo K, Ohara M, Tachikawa M, Cavallari LH, Lee MTM , Wen MS, Scordo MG, Nutescu EA, Perera MA, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Takahashi H. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.. The pharmacogenomics journal. 2017;17(6):494-500. doi:10.1038/tpj.2016.57.

  • Manzoor BS, Cheng WH, Lee JC, Uppuluri E, Nutescu EA. Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review.. The Annals of pharmacotherapy. 2017;51(12):1122-1137. doi:10.1177/1060028017721241.

  • Manzoor BS, Walton SM, Sharp L, Galanter WL, Lee TA, Nutescu EA. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.. Journal of thrombosis and thrombolysis. 2017;44(4):435-441. doi:10.1007/s11239-017-1565-2.

  • Manzoor BS, Lee TA, Sharp L, Walton SM, Galanter WL, Nutescu EA. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.. Pharmacotherapy. 2017;37(10):1221-1230. doi:10.1002/phar.1989.

  • Arwood MJ, Deng J, Drozda K, Pugach O, Nutescu EA, Schmidt S, Duarte JD, Cavallari LH. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.. Clinical pharmacology and therapeutics. 2017;101(5):675-683. doi:10.1002/cpt.558.

  • Takahashi H, Ohara M, Shibata S, Lee MT, Cavallari LH, Nutescu EA, Scordo MG, Pengo V, Padrini R, Atsuda K, Matsubara H, Chen YT, Echizen H. Correlations between the enantio- and regio-selective metabolisms of warfarin.. Pharmacogenomics. 2017;18(2):133-142. doi:10.2217/pgs-2016-0149.

  • Cavallari LH, Lee CR, Duarte JD, Nutescu EA, Weitzel KW, Stouffer GA, Johnson JA. Implementation of inpatient models of pharmacogenetics programs.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016;73(23):1944-1954. doi:10.2146/ajhp150946.

  • Arwood MJ, Chumnumwat S, Cavallari LH, Nutescu EA, Duarte JD. Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.. Clinical and translational science. 2016;9(5):233-245. doi:10.1111/cts.12404.

  • Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.. Journal of thrombosis and thrombolysis. 2016;42(2):296-311. doi:10.1007/s11239-016-1363-2.

  • Stone RH, Bress AP, Nutescu EA, Shapiro NL. Upper-Extremity Deep-Vein Thrombosis: A Retrospective Cohort Evaluation of Thrombotic Risk Factors at a University Teaching Hospital Antithrombosis Clinic.. The Annals of pharmacotherapy. 2016;50(8):637-44. doi:10.1177/1060028016649601.

  • Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism.. Journal of thrombosis and thrombolysis. 2016;41(1):15-31. doi:10.1007/s11239-015-1314-3.

  • Hellenbart EL, Drambarean B, Lee JC, Nutescu EA. The evolving role of dabigatran etexilate in clinical practice. Expert Opin Pharmacother. 2015;16(13):2053-72. doi:10.1517/14656566.2015.1074179.

  • Hellenbart E, Drambarean B, Lee J, Nutescu EA. The evolving role of dabigatran etexilate in clinical practice.. Expert opinion on pharmacotherapy. 2015;16(13):2053-72.

  • Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA. Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.. Journal of medical economics. 2015;:1-9. doi:10.3111/13696998.2015.1074583.

  • Barta AL, Nutescu EA, Thompson PA, Bussey HI, Gulseth MP. Relationship between time spent at extreme International Normalized Ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2015;72(14):1188-94. doi:10.2146/ajhp140752.

  • Kovacs RJ, Flaker GC, Saxonhouse SJ, Doherty JU, Birtcher KK, Cuker A, Davidson BL, Giugliano RP, Granger CB, Jaffer AK, Mehta BH, Nutescu E, Williams KA. Practical management of anticoagulation in patients with atrial fibrillation.. Journal of the American College of Cardiology. 2015;65(13):1340-60. doi:10.1016/j.jacc.2015.01.049.

  • Nutescu EA, Crivera C, Schein JR, Bookhart BK. Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events.. International journal of clinical practice. 2015;69(3):321-7. doi:10.1111/ijcp.12519.

  • Nordstrom BL, Evans MA, Murphy BR, Nutescu EA, Schein JR, Bookhart BK. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.. Current medical research and opinion. 2015;31(3):439-47. doi:10.1185/03007995.2014.998814.

  • Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.. Thrombosis research. 2015;135(2):303-10. doi:10.1016/j.thromres.2014.11.024.

  • Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, Cavallari LH. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.. Pharmacogenetics and genomics. 2015;25(2):73-81. doi:10.1097/FPC.0000000000000108.

  • Nagai R, Ohara M, Cavallari LH, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, Takahashi H. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.. Pharmacogenomics. 2015;16(3):217-25. doi:10.2217/pgs.14.160.

  • Nutescu EA, Wittkowsky AK, Witt DM, Kaatz S, Ansell J, Burnett A, Garcia D, Lopes RD, Oertel L, Schnurr T, Streiff M, Wirth D, Crowther M. Integrating electronic health records in the delivery of optimized anticoagulation therapy.. The Annals of pharmacotherapy. 2015;49(1):125-6. doi:10.1177/1060028014548570.

  • Nutescu EA, Engle JP, Bathija S, Grim SA, Chan J, Mucksavage JJ, Ohler KH, Tesoro EP, Thielke JJ, Shapiro NL, Donnelly AJ, Garofalo J, DiDomenico RJ. Balance of academic responsibilities of clinical track pharmacy faculty in the United States: a survey of select American College of Clinical Pharmacy Practice and Research Network Members.. Pharmacotherapy. 2014;34(12):1239-49. doi:10.1002/phar.1521.

  • Kaatz S, Fu AC, AbuDagga A, LaMori J, Bookhart BK, Damaraju CV, Tan H, Schein J, Nutescu E. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.. Thrombosis research. 2014;134(4):807-13. doi:10.1016/j.thromres.2014.07.027.

  • Ansell J, Crowther M, Burnett A, Garcia D, Kaatz S, Lopes RD, Nutescu E, Oertel L, Schnurr T, Streiff M, Wirth D, Witt D, Wittkowsky A. (2014). Comment on: editorial by Husted et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel”. (Thromb Haemost 2014; 111: 781-782).. Thrombosis and haemostasis. Vol. 112. Issue 4. Page(s) 841.

  • Cavallari LH, Nutescu EA. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.. Clinical pharmacology and therapeutics. 2014;96(1):22-4. doi:10.1038/clpt.2014.78.

  • McConeghy KW, Bress A, Qato DM, Wing C, Nutescu EA. Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.. Pharmacotherapy. 2014;34(6):561-9. doi:10.1002/phar.1415.

  • Coleman CI, Limone BL, Bookhart BK, Mody SH, Nutescu EA. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.. Thrombosis research. 2014;133(5):743-9. doi:10.1016/j.thromres.2014.02.006.

  • Lee YM, Eggen J, Soni V, Drozda K, Nutescu EA, Cavallari LH. Warfarin dose requirements in a patient with the CYP2C9*14 allele.. Pharmacogenomics. 2014;15(7):909-14. doi:10.2217/pgs.14.47.

  • Owens GM, Fine C, Harrington DW, Jacobson AK, Merli GJ, Nutescu E, Schaecher KL, Vance J, Villanueva T, Waldo AL. Improving transitions of care for patients with thromboembolic disease.. The American journal of managed care. 2014;20(4 Suppl):S81-91.

  • Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.. Journal of medical economics. 2014;17(1):52-64. doi:10.3111/13696998.2013.858634.

  • Laliberté F, Nutescu EA, Lefebvre P, Rondeau-Leclaire J, Bookhart BK, LaMori JC, Damaraju CV, Schein J, Kaatz S. Risk factors associated with myocardial infarction in venous thromboembolism patients.. Current medical research and opinion. 2014;30(1):27-35. doi:10.1185/03007995.2013.852525.

  • Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S. All-cause and disease-related health care costs associated with recurrent venous thromboembolism.. Thrombosis and haemostasis. 2013;110(6):1288-97. doi:10.1160/TH13-05-0425.

  • Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JG, Cavallari LH. Feasibility of implementing a comprehensive warfarin pharmacogenetics service.. Pharmacotherapy. 2013;33(11):1156-64. doi:10.1002/phar.1329.

  • Nutescu EA, Dager WE, Kalus JS, Lewin JJ, 3rd MD, Cipolle . Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(21):1914-29. doi:10.2146/ajhp130243.

  • Smythe MA, Fanikos J, Gulseth MP, Wittkowsky AK, Spinler SA, Dager WE, Nutescu EA. Rivaroxaban: practical considerations for ensuring safety and efficacy.. Pharmacotherapy. 2013;33(11):1223-45. doi:10.1002/phar.1289.

  • Drozda K, Labinov Y, Jiang R, Thomas MR, Wong SS, Patel S, Nutescu EA, Cavallari LH. A pharmacogenetics service experience for pharmacy students, residents, and fellows.. American journal of pharmaceutical education. 2013;77(8):175. doi:10.5688/ajpe778175.

  • Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.. Lancet (London, England). 2013;382(9894):790-6. doi:10.1016/S0140-6736(13)60681-9.

  • Maddux MS. Board of Regents commentary. Qualifications of pharmacists who provide direct patient care: perspectives on the need for residency training and board certification.. Pharmacotherapy. 2013;33(8):888-91. doi:10.1002/phar.1285.

  • Reardon G, Pandya N, Nutescu EA, Lamori J, Damaraju CV, Schein J, Bookhart B. Incidence of venous thromboembolism in nursing home residents.. Journal of the American Medical Directors Association. 2013;14(8):578-84. doi:10.1016/j.jamda.2013.02.003.

  • Cavallari LH, Nutescu EA, Duarte JD. Personalized medicine in cardiology: the time for genotype-guided therapy is now.. Future cardiology. 2013;9(4):459-64. doi:10.2217/fca.13.35.

  • Baker WL, Marrs JC, Davis LE, Nutescu EA, Rowe AS, Ryan M, Splinter MY, Vardeny O, Fagan SC. (2013). Key articles and guidelines in the acute management and secondary prevention of ischemic stroke.. Pharmacotherapy. Vol. 33. Issue 6. Page(s) e115-42.

  • Baker WL, Marrs JC, Davis LE, Nutescu EA, Rowe AS, Ryan M, Splinter MY, Vardeny O, Fagan SC. (2013). Key articles and guidelines in the primary prevention of ischemic stroke.. Pharmacotherapy. Vol. 33. Issue 6. Page(s) e101-14.

  • Nutescu EA. Oral anticoagulant therapies: balancing the risks.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(10 Suppl 1):S3-11. doi:10.2146/ajhp130040.

  • Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum.. The Annals of pharmacotherapy. 2013;47(5):714-24. doi:10.1345/aph.1R634.

  • Nutescu EA. Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA.. Expert opinion on pharmacotherapy. 2013;14(4):525-34. doi:10.1517/14656566.2013.774374.

  • Nutescu EA, Bautista A, Gao W, Galanter WL, Schumock GT, Mody SH, Bookhart BK, Lambert BL. Warfarin anticoagulation after total hip or total knee replacement: clinical and resource-utilization outcomes in a university-based antithrombosis clinic.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(5):423-30. doi:10.2146/ajhp120341.

  • Reardon G, Pandya N, Nutescu EA, Lamori J, Damaraju CV, Schein J, Bookhart BK. Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.. The American journal of geriatric pharmacotherapy. 2012;10(6):361-72. doi:10.1016/j.amjopharm.2012.11.003.

  • Nutescu E. Apixaban: a novel oral inhibitor of factor Xa.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2012;69(13):1113-26. doi:10.2146/ajhp110418.

  • Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.. Journal of managed care pharmacy : JMCP. 2012;18(5):363-74.

  • Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.. Clinical pharmacology and therapeutics. 2012;91(4):660-5. doi:10.1038/clpt.2011.269.

  • Cavallari LH, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-Michaels K, Viana MA, Shapiro NL, Nutescu EA. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.. Pharmacogenetics and genomics. 2012;22(2):152-8. doi:10.1097/FPC.0b013e32834f288f.

  • Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.. Journal of medical economics. 2012;15(4):644-53. doi:10.3111/13696998.2012.669438.

  • Nutescu EA, Bathija S, Sharp LK, Gerber BS, Schumock GT, Fitzgibbon ML. Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption.. Pharmacotherapy. 2011;31(12):1161-74. doi:10.1592/phco.31.12.1161.

  • Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.. Pharmacotherapy. 2011;31(12):1232-49. doi:10.1592/phco.31.12.1232.

  • Martin MT, Nutescu EA. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.. Current medical research and opinion. 2011;27(11):2123-31. doi:10.1185/03007995.2011.619178.

  • Nordstrom BL, Kachroo S, Fraeman KH, Nutescu EA, Schein JR, Fisher A, Bookhart BK. Warfarin prophylaxis in patients after total knee or hip arthroplasty–international normalized ratio patterns and venous thromboembolism.. Current medical research and opinion. 2011;27(10):1973-85. doi:10.1185/03007995.2011.614938.

  • Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, Viana MA, Shapiro NL, Nutescu EA. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients.. Pharmacotherapy. 2011;31(8):785-92. doi:10.1592/phco.31.8.785.

  • Tiryaki F, Nutescu EA, Hennenfent JA, Karageanes AM, Koesterer LJ, Lambert BL, Schumock GT. Anticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2011;68(13):1239-44. doi:10.2146/ajhp100543.

  • Shapiro NL, Kominiarek MA, Nutescu EA, Chevalier AB, Hibbard JU. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.. Pharmacotherapy. 2011;31(7):678-85. doi:10.1592/phco.31.7.678.

  • Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.. Journal of thrombosis and thrombolysis. 2011;31(3):326-43. doi:10.1007/s11239-011-0561-1.

  • Martin MT, Spinler SA, Nutescu EA. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.. Clinical therapeutics. 2011;33(4):425-42. doi:10.1016/j.clinthera.2011.04.007.

  • Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics.. Blood cells, molecules & diseases. 2011;46(2):147-50. doi:10.1016/j.bcmd.2010.11.005.

  • Nutescu E. Characteristics of novel anticoagulants and potential economic implications.. The American journal of managed care. 2011;17(1 Suppl):S27-32.

  • Stubbings J, Nutescu E, Durley SF, Bauman JL. (2011). Payment for clinical pharmacy services revisited.. Pharmacotherapy. Vol. 31. Issue 1. Page(s) 1-8.

  • Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.. Journal of medical economics. 2011;14(3):324-34. doi:10.3111/13696998.2011.578698.

  • Wittkowsky AK, Spinler SA, Dager W, Gulseth MP, Nutescu EA. Dosing guidelines, not protocols, for managing warfarin therapy.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2010;67(18):1554-6. doi:10.2146/ajhp100064.

  • Martin MT, Kuchta AM, Nutescu EA. A clinician’s guide to perioperative bridging for patients on oral anticoagulation.. Journal of pharmacy practice. 2010;23(4):303-12. doi:10.1177/0897190010363276.

  • Galanter WL, Thambi M, Rosencranz H, Shah B, Falck S, Lin FJ, Nutescu E, Lambert B. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2010;67(15):1265-73. doi:10.2146/ajhp090575.

  • Smythe MA, Nutescu EA, Wittkowsky AK. (2010). Changes in the USP heparin monograph and implications for clinicians.. Pharmacotherapy. Vol. 30. Issue 5. Page(s) 428-31.

  • Nutescu EA. (2010). Anticoagulation management services: entering a new era.. Pharmacotherapy. Vol. 30. Issue 4. Page(s) 327-9.

  • Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA. Genetic and clinical predictors of warfarin dose requirements in African Americans.. Clinical pharmacology and therapeutics. 2010;87(4):459-64. doi:10.1038/clpt.2009.223.

  • Zarowitz BJ, Tangalos E, Lefkovitz A, Bussey H, Deitelzweig S, Nutescu E, O’Shea T, Resnick B, Wheeler A. Thrombotic risk and immobility in residents of long-term care facilities.. Journal of the American Medical Directors Association. 2010;11(3):211-21. doi:10.1016/j.jamda.2009.11.006.

  • Markel Vaysman A, Nutescu EA. YM-150, a Factor Xa inhibitor for the prevention of venous thromboembolism and coronary artery disease.. Current opinion in investigational drugs (London, England : 2000). 2010;11(3):333-9.

  • Dobesh PP, Wittkowsky AK, Stacy Z, Dager WE, Trujillo TC, Gulseth MP, Nutescu E, Vondracek T. Key articles and guidelines in the treatment of venous thromboembolism.. Pharmacotherapy. 2009;29(11):1385. doi:10.1592/phco.29.11.1385.

  • Nochowitz B, Shapiro NL, Nutescu EA, Cavallari LH. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population.. The Annals of pharmacotherapy. 2009;43(7):1165-72. doi:10.1345/aph.1L707.

  • Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.. The Annals of pharmacotherapy. 2009;43(6):1064-83. doi:10.1345/aph.1L194.

  • Cavallari LH, Aston JL, Momary KM, Shapiro NL, Patel SR, Nutescu EA. Predictors of unstable anticoagulation in African Americans.. Journal of thrombosis and thrombolysis. 2009;27(4):430-7. doi:10.1007/s11239-008-0236-8.

  • Dobesh PP, Wittkowsky AK, Stacy Z, Dager WE, Haines ST, Lopez LM, Nutescu E, Phillips KW, Trujillo TC, Vondracek T. (2009). Key articles and guidelines for the prevention of venous thromboembolism.. Pharmacotherapy. Vol. 29. Issue 4. Page(s) 410-58.

  • Ripley TL, Nutescu E. Anticoagulation in patients with heart failure and normal sinus rhythm.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2009;66(2):134-41. doi:10.2146/ajhp080047.

  • Momary KM, Shapiro NL, Brace LD, Shord SS, Grossi E, Viana MA, Helgason CM, Nutescu EA, Cavallari LH. Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke.. Cerebrovascular diseases (Basel, Switzerland). 2009;27(6):585-93. doi:10.1159/000214223.

  • Wittkowsky AK, Nutescu EA, Devine EB. Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?. Journal of thrombosis and thrombolysis. 2008;26(3):248-50. doi:10.1007/s11239-007-0176-8.

  • Nutescu EA, Shorr AF, Farrelly E, Horblyuk R, Happe LE, Franklin M. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery.. The Annals of pharmacotherapy. 2008;42(9):1216-21. doi:10.1345/aph.1L135.

  • Shorr AF, Nutescu EA, Farrelly E, Horblyuk R, Happe LE, Franklin M. Postdischarge oral versus injectable anticoagulation following major orthopedic surgery.. The Annals of pharmacotherapy. 2008;42(9):1222-8. doi:10.1345/aph.1L113.

  • Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2008;65(16):1520-9. doi:10.2146/ajhp070624.

  • Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum.. The Annals of pharmacotherapy. 2008;42(7):979-88. doi:10.1345/aph.1L098.

  • Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors.. Cardiology clinics. 2008;26(2):169-87, v-vi. doi:10.1016/j.ccl.2007.12.005.

  • Nutescu EA, Steinmetz Pater K. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.. Expert opinion on pharmacotherapy. 2008;9(1):95-105. doi:10.1517/14656566.9.1.95.

  • Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, Hamersley SL, Hyers TM, Katz V, Kuhlmann R, Nutescu EA, Thorp JA, Zehnder JL. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes.. American journal of obstetrics and gynecology. 2007;197(5):457.e1-21. doi:10.1016/j.ajog.2007.04.022.

  • Nutescu EA. ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2007;64(21):2281-91. doi:10.2146/ajhp070301.

  • Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans.. Pharmacogenomics. 2007;8(11):1535-44. doi:10.2217/14622416.8.11.1535.

  • Grogan KM, Wong C, Nutescu EA, Shord SS. Examining differences in weekly warfarin dose in patients with and without cancer.. Therapeutic drug monitoring. 2007;29(5):638-43. doi:10.1097/FTD.0b013e318074dc46.

  • Bottorff MB, Nutescu EA, Spinler S. Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.. Pharmacotherapy. 2007;27(8):1145-62. doi:10.1592/phco.27.8.1145.

  • Nutescu EA. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2007;64(11 Suppl 7):S5-13. doi:10.2146/ajhp070108.

  • Kominiarek MA, Angelopoulos SM, Shapiro NL, Studee L, Nutescu EA, Hibbard JU. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications.. Journal of perinatology : official journal of the California Perinatal Association. 2007;27(6):329-34. doi:10.1038/sj.jp.7211745.

  • Vats V, Nutescu EA, Theobald JC, Wojtynek JE, Schumock GT. Survey of hospitals for guidelines, policies, and protocols for anticoagulants.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2007;64(11):1203-8. doi:10.2146/ajhp060264.

  • Nutescu EA, Klotz RS. Basic terminology in obtaining reimbursement for pharmacists’ cognitive services.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2007;64(2):186-92. doi:10.2146/ajhp060234.

  • Nutescu EA. Anticoagulant agents are mainstay therapies in the prevention and treatment of arterial and venous thrombosis. Introduction.. The American journal of managed care. 2006;12(16 Suppl):S427-9.

  • Nutescu EA, Pater K. Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.. IDrugs : the investigational drugs journal. 2006;9(12):854-65.

  • Nutescu EA. Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapies.. The American journal of managed care. 2006;12(16 Suppl):S444-50.

  • Wittkowsky AK, Nutescu EA, Blackburn J, Mullins J, Hardman J, Mitchell J, Vats V. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting.. Chest. 2006;130(5):1385-9. doi:10.1378/chest.130.5.1385.

  • Nutescu EA. Economic considerations in managing patients with chronic stable angina.. Journal of managed care pharmacy : JMCP. 2006;12(8 Suppl):S17-21.

  • Nutescu EA, Wittkowsky AK, Dobesh PP, Hawkins DW, Dager WE. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.. The Annals of pharmacotherapy. 2006;40(9):1558-71. doi:10.1345/aph.1G577.

  • Wittkowsky AK, Downing J, Blackburn J, Nutescu E. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic.. Thrombosis and haemostasis. 2006;96(2):137-41.

  • Cavallari LH, Helgason CM, Brace LD, Viana MA, Nutescu EA. Sex difference in the antiplatelet effect of aspirin in patients with stroke.. The Annals of pharmacotherapy. 2006;40(5):812-7. doi:10.1345/aph.1G569.

  • Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements.. Expert opinion on drug safety. 2006;5(3):433-51. doi:10.1517/14740338.5.3.433.

  • Sullivan SD, Kwong L, Nutescu E. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2006;9(2):68-76. doi:10.1111/j.1524-4733.2006.00085.x.

  • Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.. Pharmacogenetics and genomics. 2006;16(2):101-10.

  • Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors.. Clinics in geriatric medicine. 2006;22(1):33-56, viii. doi:10.1016/j.cger.2005.09.009.

  • Nutescu EA, Park HY, Walton SM, Blackburn JC, Finley JM, Lewis RK, Schumock GT. Factors that influence prescribing within a therapeutic drug class.. Journal of evaluation in clinical practice. 2005;11(4):357-65. doi:10.1111/j.1365-2753.2005.00545.x.

  • Nutescu EA, Wittkowsky AK, Dager WE. (2005). Uncertain times for oral anticoagulation therapy.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. Vol. 62. Issue 14. Page(s) 1449.

  • Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.. The Annals of pharmacotherapy. 2005;39(7-8):1275-85. doi:10.1345/aph.1E524.

  • Nutescu EA, Helgason CM. Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.. Current treatment options in cardiovascular medicine. 2005;7(3):241-50.

  • Spinler SA, Nutescu EA, Smythe MA, Wittkowsky AK. Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors.. The Annals of pharmacotherapy. 2005;39(6):1049-55. doi:10.1345/aph.1E118.

  • Nutescu EA, Shapiro NL, Chevalier A, Amin AN. A pharmacologic overview of current and emerging anticoagulants.. Cleveland Clinic journal of medicine. 2005;72 Suppl 1:S2-6.

  • Haines ST, Nutescu EA. Current and emerging treatment options for venous thrombosis: a case discussion.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2005;62(6):593-605.

  • Wittkowsky AK, Sekreta CM, Nutescu EA, Ansell J. Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners.. Pharmacotherapy. 2005;25(2):265-9. doi:10.1592/phco.25.2.265.56949.

  • Nutescu EA. Emerging options in the treatment of venous thromboembolism.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2004;61(23 Suppl 7):S12-7.

  • Bongiorno RA, Nutescu EA. Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers.. Seminars in thrombosis and hemostasis. 2004;30(6):619-26. doi:10.1055/s-2004-861503.

  • Nutescu EA. Point of care monitors for oral anticoagulant therapy.. Seminars in thrombosis and hemostasis. 2004;30(6):697-702. doi:10.1055/s-2004-861512.

  • Nutescu EA. Strategies for cost-effective prevention and treatment of venous thromboembolism. Introduction.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2004;61(23 Suppl 7):S3-4.

  • Nutescu EA, Helgason CM, Briller J, Schwertz DW. New blood thinner offers first potential alternative in 50 years: ximelagatran.. The Journal of cardiovascular nursing. 2004;19(6):374-83.

  • Dager WE, Vondracek TG, McIntosh BA, Nutescu EA. Ximelagatran: an oral direct thrombin inhibitor.. The Annals of pharmacotherapy. 2004;38(11):1881-97. doi:10.1345/aph.1E078.

  • Schumock GT, Blackburn JC, Nutescu EA, Walton SM, Finley JM, Lewis RK. Impact of prescribing guidelines for inpatient anticoagulation.. The Annals of pharmacotherapy. 2004;38(10):1570-5. doi:10.1345/aph.1E121.

  • Nutescu EA, Spinler SA, Dager WE, Bussey HI. Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management.. Pharmacotherapy. 2004;24(10 Pt 2):199S-202S.

  • Nutescu EA, Pickard AS, Blackburn JC, Wittkowsky AK, Ansell J, Schumock GT. Impact of oral direct thrombin inhibitors on anticoagulation clinics.. Pharmacotherapy. 2004;24(9):1204-12.

  • Nutescu EA, Spyropoulos AC, Cranmer KW. Oral anticoagulation: preparing for change.. Journal of the American Medical Directors Association. 2004;5(5 Suppl 1):2-11.

  • Nutescu EA, Bauman JL. (2004). Shifting paradigms in oral anticoagulation management.. Journal of cardiovascular pharmacology and therapeutics. Vol. 9. Issue 3. Page(s) 149-50.

  • Nutescu E, Singh-Khalsa M. Treatment of venous thromboembolism: challenging the unfractionated heparin standard.. Pharmacotherapy. 2004;24(8 Pt 2):127S-131S.

  • Nutescu EA, Helgason CM. Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.. Pharmacotherapy. 2004;24(7 Pt 2):82S-87S.

  • Dager WE, Andersen J, Nutescu E. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.. Pharmacotherapy. 2004;24(7 Pt 2):88S-94S.

  • Wittkowsky AK, Whitely KS, Devine EB, Nutescu E. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin.. Pharmacotherapy. 2004;24(5):600-5.

  • Schumock GT, Walton SM, Park HY, Nutescu EA, Blackburn JC, Finley JM, Lewis RK. Factors that influence prescribing decisions.. The Annals of pharmacotherapy. 2004;38(4):557-62. doi:10.1345/aph.1D390.

  • Helgason CM, Do MA, Nutescu E. Warfarin in patients with stroke and reasons for discontinuation.. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2004;13(2):70-3. doi:10.1016/j.jstrokecerebrovasdis.2004.01.006.

  • Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation.. The Annals of pharmacotherapy. 2004;38(1):99-109. doi:10.1345/aph.1D066.

  • Nutescu EA, Shapiro NL, Feinstein H, Rivers CW. Tinzaparin: considerations for use in clinical practice.. The Annals of pharmacotherapy. 2003;37(12):1831-40. doi:10.1345/aph.1D221.

  • Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor.. Pharmacotherapy. 2003;23(11):1463-74.

  • Nutescu EA. Antithrombotic therapy for the treatment of venous thromboembolism.. The American journal of managed care. 2003;9(5 Suppl):S103-14; quiz S115-20.

  • Nutescu EA. The future of anticoagulation clinics.. Journal of thrombosis and thrombolysis. 2003;16(1-2):61-3. doi:10.1023/B:THRO.0000014595.46367.89.

  • Peters PC, Jr E, Nutescu J, Andersen . Wound pharmacobiology.. Orthopedics. 2003;26(8 Suppl):s837-42.

  • Nutescu EA, Lewis RK, Finley JM, Schumock GT. Hospital guidelines for use of low-molecular-weight heparins.. The Annals of pharmacotherapy. 2003;37(7-8):1072-81.

  • Nutescu E, Racine E. Traditional versus modern anticoagulant strategies: summary of the literature.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2002;59(20 Suppl 6):S7-14.

  • Fraser M, Nutescu E, Jacobs LG. Anticoagulation in long-term care: the state of the art.. Journal of the American Medical Directors Association. 2002;3(4 Suppl):H17-20.

  • Schumock GT, Nutescu EA, Walton SM, Arondekar BV, Lewis RK. Survey of hospital policies regarding low-molecular-weight heparins.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2002;59(6):534-8.

  • Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations.. Pharmacotherapy. 2001;21(2):218-34.

  • Shek KL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited.. Pharmacotherapy. 1999;19(10):1153-8.

  • Nutescu E, Hunt C, Teeters J. Multidisciplinary approach to improving allergy documentation.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1998;55(4):364-8.

    • Education

  • MS, Clinical and Translational Science, University of Illinois at Chicago, School of Public Health, Chicago, IL

  • Primary Care Specialty Residency, University of Illinois at Chicago Medical Center, Chicago, IL

  • Pharmacy Practice Residency, Lutheran General Hospital/Advocate Health Care, Chicago, IL

  • PharmD, Doctor of Pharmacy with high-honors, University of Illinois at Chicago, College of Pharmacy, Chicago, IL

  • BS, Chemical Engineering, Polytechnical Institute, Bucharest, Romania